Showing results (361-370 of 421) with videos related to

Sort By:
Pageof 43
Hepatology (Baltimore, Md.)|November 3, 2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseAndrew J Muir, Fred F Poordad, John G McHutchison, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|January 22, 2008
Initial association of NR2E1 with bipolar disorder and identification of candidate mutations in bipolar disorder, schizophrenia, and aggression through resequencingRavinesh A Kumar, Kevin A McGhee, Stephen Leach, et al.
Biochemical Society Transactions|March 20, 2010
Confirmed rare copy number variants implicate novel genes in schizophreniaGloria W C Tam, Louie N van de Lagemaat, Richard Redon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Hepatology (Baltimore, Md.)|January 29, 2011
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVRAlexander J Thompson, Rosanna Santoro, Valeria Piazzolla, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PROZobair M Younossi, Arian Afendy, Maria Stepanova, et al.
The New England Journal of Medicine|April 9, 2010
Telaprevir for previously treated chronic HCV infectionJohn G McHutchison, Michael P Manns, Andrew J Muir, et al.
Pageof 43